Takeda launches CINRYZE™ in India, the first C1-I NH for prophylaxis in hereditary angioedema patients
Takeda, a global values-driven, R&D focused biopharmaceutical leader has launched Cinryze; an innovative injectable prescription medicine for the treatment of hereditary angioedema (HAE) patients. The medication is effective on HAE patients between 2-6 years above of age and…








